• About Us
  • Advertise
  • Contact Us
  • Privacy Policy
Sunday, April 18, 2021
45 °f
Platte
52 ° Mon
37 ° Tue
37 ° Wed
42 ° Thu
The Platte County Landmark Newspaper
  • Home
  • Local News
  • Opinion
  • Landmark Live!
  • Looking Backward
  • Home
  • Local News
  • Opinion
  • Landmark Live!
  • Looking Backward
No Result
View All Result
The Platte County Landmark Newspaper
No Result
View All Result

Experimental COVID-19 vaccine has been ‘well-tolerated’

Landmark Staff by Landmark Staff
July 17, 2020
in Platte County
COVID-19
5
SHARES
129
VIEWS
Share on FacebookShare on TwitterShare via Email

An investigational vaccine, mRNA-1273, designed to protect against SARS-CoV-2, the virus that causes coronavirus disease 2019 (COVID-19), was generally well tolerated and prompted neutralizing antibody activity in healthy adults, according to interim results published online this week in The New England Journal of Medicine.

The ongoing Phase 1 trial is supported by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. The experimental vaccine is being co-developed by researchers at NIAID and at Moderna, Inc. of Cambridge, Massachusetts. Manufactured by Moderna, mRNA-1273 is designed to induce neutralizing antibodies directed at a portion of the coronavirus “spike” protein, which the virus uses to bind to and enter human cells.

RelatedNews

Major addition set at Zona Rosa

Trail connection celebrated

Judge tells city attorney ‘put case on front burner’

The trial was led by Lisa A. Jackson, M.D., MPH, of Kaiser Permanente Washington Health Research Institute in Seattle, where the first participant received the candidate vaccine on March 16. This interim report details the initial findings from the first 45 participants ages 18 to 55 years enrolled at the study sites in Seattle and at Emory University in Atlanta. Three groups of 15 participants received two intramuscular injections, 28 days apart, of either 25, 100 or 250 micrograms (mcg) of the investigational vaccine. All the participants received one injection; 42 received both scheduled injections.

In April, the trial was expanded to enroll adults older than age 55 years; it now has 120 participants. However, the newly published results cover the 18 to 55-year age group only.

Regarding safety, no serious adverse events were reported. More than half of the participants reported fatigue, headache, chills, myalgia or pain at the injection site. Systemic adverse events were more common following the second vaccination and in those who received the highest vaccine dose. Data on side effects and immune responses at various vaccine dosages informed the doses used or planned for use in the Phase 2 and 3 clinical trials of the investigational vaccine.

The interim analysis includes results of tests measuring levels of vaccine-induced neutralizing activity through day 43 after the second injection. Two doses of vaccine prompted high levels of neutralizing antibody activity that were above the average values seen in convalescent sera obtained from persons with confirmed COVID-19 disease.

A Phase 2 clinical trial of mRNA-1273, sponsored by Moderna, began enrollment in late May. Plans are underway to launch a Phase 3 efficacy trial in July 2020.

Tags: covid-19
Landmark Staff

Landmark Staff

Related Posts

J&J vaccine paused; local officials request rescheduling

J&J vaccine paused; local officials request rescheduling

by Landmark Digital Staff
April 13, 2021
0

Have an appointment today in Platte County? Reschedule Platte County Health Department will pause on the Johnson and Johnson vaccine after recommendations from the Food and Drug Administration (FDA) and Centers for Disease Control (CDC). Anyone who has an appointment...

Vaccine side effects; taking the temperature of local voters

Vaccine side effects; taking the temperature of local voters

by Ivan Foley
April 9, 2021
0

Welcome to spring. And welcome to grilling season. I don't have many skills in the kitchen but my work on the patio is impeccable. At least that's what I tell myself. When grilling always use a condiment. Let's talk the...

Landmark Live with Mayor Quinton Lucas

Whats new in KC with Quinton Lucas

by Ivan Foley
April 8, 2021
0

https://youtu.be/93-FffZH-hA hey everybody welcome in it's another episode of landmark live it's a production of the platte county landmark newspaper we are thrilled to have you with us i'm...

Mayor Quinton Lucas

Landmark Live will feature Quinton Lucas

by Ivan Foley
April 6, 2021
0

Quinton Lucas, the mayor of Kansas City, will join the guys from Landmark Live for a conversation during the Thursday, April 8 episode of Landmark Live. The show, with hosts Ivan Foley and Brad Carl, will begin at 6 p.m....

Next Post

Advice for the health department

Popular News

  • Major subdivision planned along Crooked Road

    Major subdivision planned along Crooked Road

    42 shares
    Share 17 Tweet 11
  • Judge tells city attorney ‘put case on front burner’

    18 shares
    Share 7 Tweet 5
  • City, state will team up to repair Hwy. 92

    13 shares
    Share 5 Tweet 3
  • A Parkville speakeasy; slow-paced courtroom drama

    8 shares
    Share 3 Tweet 2
  • Say no to new tax

    8 shares
    Share 3 Tweet 2
  • About Us
  • Advertise
  • Contact Us
  • Privacy Policy
Call us at 816-858-0363

Copyright © 2019-2020 The Platte County Landmark Newspaper - All Rights Reserved

No Result
View All Result
  • Home
  • Subscribe Online
  • Local News
  • Opinion
  • Landmark Live!
  • Looking Backward

Copyright © 2019-2020 The Platte County Landmark Newspaper - All Rights Reserved

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Add New Playlist